Subjects with or without T2D present obvious differences for new-onset of HF (P = 0.005) and HF subtypes (P = 0.013); the differences remain significant upon factoring the medications in the analyses, such as mineralocorticoid receptor antagonist (MRA, P = 0.047), BBs (P = 0.015), and renin-angiotensin system inhibitors (RSIs, P < 0.001) at the end of follow-up. The gene discussed is NR3C2; the disease is type 2 diabetes mellitus.